WuXi AppTec Co., Ltd. (WUXIF)
| Market Cap | 27.09B |
| Revenue (ttm) | 5.49B |
| Net Income (ttm) | 1.15B |
| Shares Out | n/a |
| EPS (ttm) | 0.39 |
| PE Ratio | 23.56 |
| Forward PE | n/a |
| Dividend | 0.14 (1.71%) |
| Ex-Dividend Date | Jun 17, 2024 |
| Volume | 39 |
| Average Volume | 89 |
| Open | 6.16 |
| Previous Close | 6.16 |
| Day's Range | 6.16 - 8.12 |
| 52-Week Range | 3.74 - 8.12 |
| Beta | 0.84 |
| RSI | 93.95 |
| Earnings Date | Mar 18, 2025 |
About WuXi AppTec
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categ... [Read more]
Financial Performance
In 2023, WuXi AppTec's revenue was 40.34 billion, an increase of 2.51% compared to the previous year's 39.35 billion. Earnings were 9.61 billion, an increase of 9.00%.
Financial numbers in CNY Financial StatementsNews
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI , Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ind...
WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year
SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating
COUVET, Switzerland , Nov. 14, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life s...
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
SHANGHAI , Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-...
WuXi AppTec to raise $500 mln in convertible bond sale as US restrictions loom
China's WuXi AppTec , will raise $500 million in a convertible bond sale, according to a regulatory filing on Tuesday, a month after the U.S. passed rules to restrict business with the firm on nationa...
US bill to restrict business with China's WuXi AppTec, BGI passes House
The U.S. House of Representatives on Monday passed a bill that aims to restrict business with China's WuXi AppTec , BGI and several other biotech companies on national security grounds.
US House committee to vote on bill to restrict BGI, WuXi AppTec
U.S. legislation that would restrict business with China's BGI, WuXi AppTec and certain other biotech companies on national security grounds will be voted on by a committee in the House of Representat...
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties
A new version of a bill that would restrict U.S. business with China's WuXi AppTec, BGI and other biotechnology companies of concern would allow companies until 2032 to end work with the Chinese firms...
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reac...
Exclusive: China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators
U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without...
China's WuXi AppTec In Crosshairs of US Draft Biosecurity Bill
A draft US law is casting a cloud over some Chinese pharma firms, as it aims to block certain foreign biotech companies from accessing US federal contracts on national security grounds. Bloomberg's Mi...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributable to the Owners of the Company [1] Increased 9.0% to RMB9,607 Million; Dilut...
WuXi AppTec Says It Left Washington Lobbying Group Voluntarily
The trade group has since updated its statement on Thursday, saying that WuXi AppTec “proactively ended its membership in BIO.”
WuXi Shares Fall as Washington Lobbying Group Cuts Ties
WuXi AppTec and its affiliates are taking another beating after the loss of support from the biotech industry's top lobbying group in Washington, as two bills targeting Chinese biotech companies wind ...
US Senate committee takes up bill targeting China's BGI, WuXi Apptec
A bill in the U.S. Senate that would restrict business with China's BGI, WuXi Apptec and other biotech companies on national security grounds faces its first big test in Congress on Wednesday.
China's WuXi AppTec says it poses no national security risks to US
Chinese biotech firm WuXi AppTec said on Sunday that it posed no national security risks to the United States, following calls by U.S. lawmakers for sanctions on the Shanghai-listed company.
U.S. Lawmakers Seek Investigation Against China's WuXi AppTec
Lawmakers in the U.S. have written to various government bodies, seeking to investigate Chinese biotech company WuXi AppTec over alleged ties to the Chinese military.
WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excl...
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022
Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Yea...